Biosimilar Competition Intensifies Global Market Shift
The Erythropoietin Drugs Market has witnessed an influx of biosimilars following the expiration of key patents. These alternatives offer comparable efficacy at reduced costs, appealing to healthcare systems under budget constraints.
In emerging economies, biosimilars are helping expand treatment access to previously underserved populations. Leading players are responding with competitive pricing, partnerships, and patient support programs to retain market share. This trend marks a pivotal moment, as affordability becomes as critical as innovation in shaping the future market landscape.
1 View